Straumann Holding AG (OTCMKTS:SAUHY – Get Free Report) saw a significant growth in short interest in June. As of June 30th, there was short interest totaling 46,964 shares, a growth of 2,398.1% from the June 15th total of 1,880 shares. Based on an average trading volume of 83,081 shares, the short-interest ratio is presently 0.6 days. Currently, 0.0% of the company’s stock are sold short.
Straumann Stock Performance
OTCMKTS SAUHY traded up $0.18 on Friday, hitting $13.03. 78,950 shares of the stock were exchanged, compared to its average volume of 37,098. The business’s fifty day moving average is $11.97 and its 200 day moving average is $11.65. Straumann has a 52 week low of $9.44 and a 52 week high of $14.11.
Analyst Upgrades and Downgrades
SAUHY has been the topic of several research reports. BMO Capital Markets began coverage on shares of Straumann in a research report on Wednesday. They issued an “outperform” rating on the stock. Citigroup reiterated a “sell” rating on shares of Straumann in a report on Thursday. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Straumann in a research note on Tuesday, June 30th. Morgan Stanley reiterated an “underweight” rating on shares of Straumann in a report on Tuesday, June 30th. Finally, Barclays restated an “overweight” rating on shares of Straumann in a research note on Thursday, June 18th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Straumann currently has a consensus rating of “Hold”.
Straumann Company Profile
Straumann (OTCMKTS:SAUHY) is a Swiss-based dental technology company that develops, manufactures and markets restorative, regenerative and digital solutions for dental professionals. The company’s core offerings center on implant-supported restorations and components, biomaterials used for bone and soft-tissue regeneration, and a range of prosthetic products used by dentists and dental laboratories to restore oral function and aesthetics.
In addition to implant and biomaterial product lines, Straumann provides digital dentistry solutions that support treatment planning and workflows.
Read More
- Five stocks we like better than Straumann
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
- Micron’s $250 Billion Bet Could Reshape the AI Memory Race
- Rocket Lab’s Stock Drop Comes With a Bullish Twist
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
Receive News & Ratings for Straumann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Straumann and related companies with MarketBeat.com's FREE daily email newsletter.
